ATE74272T1 - Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie. - Google Patents

Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.

Info

Publication number
ATE74272T1
ATE74272T1 AT87100809T AT87100809T ATE74272T1 AT E74272 T1 ATE74272 T1 AT E74272T1 AT 87100809 T AT87100809 T AT 87100809T AT 87100809 T AT87100809 T AT 87100809T AT E74272 T1 ATE74272 T1 AT E74272T1
Authority
AT
Austria
Prior art keywords
human
treatment
pharmaceutical agent
csf
leukemia
Prior art date
Application number
AT87100809T
Other languages
English (en)
Inventor
Masahiko Tamura
Kunihiro Hattori
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE74272T1 publication Critical patent/ATE74272T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT87100809T 1986-01-22 1987-01-21 Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie. ATE74272T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1028186 1986-01-22
EP87100809A EP0231819B1 (de) 1986-01-22 1987-01-21 Pharmazeutischer Stoff für die Behandlung von myelogener Leukämie

Publications (1)

Publication Number Publication Date
ATE74272T1 true ATE74272T1 (de) 1992-04-15

Family

ID=11745925

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87100809T ATE74272T1 (de) 1986-01-22 1987-01-21 Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.

Country Status (5)

Country Link
EP (1) EP0231819B1 (de)
AT (1) ATE74272T1 (de)
CA (1) CA1297005C (de)
DE (1) DE3777845D1 (de)
ES (1) ES2036530T3 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19860801A1 (de) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Rekombinanter Wachstumsfaktor mit der biologischen Aktivität eines G-CSF (Granulocyte Colony Stimulating Factor)
WO2001017542A1 (fr) 1999-09-08 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Preparation de solution de proteines et procede de stabilisation associe
KR100408429B1 (ko) * 2000-01-24 2003-12-06 한미약품 주식회사 유즙 중에 인간 과립구 콜로니 자극인자를 생산하는형질전환 흑염소
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
EP1463751B1 (de) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albuminfusionsproteine
EP1541585B1 (de) 2002-08-27 2013-01-30 Biokine Therapeutics Ltd. Cxcr4-antagonist und dessen verwendung
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
ES2842210T3 (es) 2006-12-21 2021-07-13 Biokine Therapeutics Ltd 4F-benzoil-TN14003 para la movilización de células progenitoras hematopoyéticas con vistas al trasplante
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
ES2462517T3 (es) 2009-06-14 2014-05-23 Biokine Therapeutics Ltd. Terapia con péptidos para aumentar los niveles de plaquetas
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2908627A1 (de) * 1979-03-06 1980-09-11 Bayer Ag Neue trishydroxyalkylheterocyclen
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
ATE65798T1 (de) * 1985-02-08 1991-08-15 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-koloniestimulierungsfaktor.

Also Published As

Publication number Publication date
EP0231819B1 (de) 1992-04-01
DE3777845D1 (de) 1992-05-07
EP0231819A3 (en) 1989-03-08
ES2036530T3 (es) 1993-06-01
CA1297005C (en) 1992-03-10
EP0231819A2 (de) 1987-08-12

Similar Documents

Publication Publication Date Title
ATE71662T1 (de) Einen menschlichen granulozytkoloniereizfaktor fuer die behandlung von leukopenien enthaltende pharmazeutische zubereitung.
ATE74272T1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DE3771509D1 (de) Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE69007744D1 (de) Verwendung von Interleukin 2 zur Behandlung von Leukämien.
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE69034076D1 (de) Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
ATE66375T1 (de) Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur systemischen behandlung von verschiedenen erkrankungen des menschen in niedriger dosierung.
DE3750248T2 (de) Zubereitung und Behandlung der Haut mit Human-Leukocyten-Interferon.
ZA9010409B (en) Utilisation of a polypeptide with human 2 interleukine activity in the preparation of a pharmaceutical composition for the treatment of epithelial malignant tumours
Seki et al. Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line
ZA887181B (en) A method for the preparation of a pharmaceutical curative for the veterinary and humane medicine,with antiviral and antitumoral effect
DE69005837D1 (de) Verwendung bestimmter gamma-Interferone zur Behandlung von Krebs des Ovars.
GR950100316A (el) Φαρμακευτικο παρασκευασμα βασιζομενο σε αιωρημα εμβρυικων κυτταρων με δραση ανοσοποιητικης υποκαταστασης και μεθοδος θεραπειας του συνδρομου της επικτητης μολυνσης ανοσοποιητικης ανεπαρκειας (hiv) με τη χρηση αυτου του παρασκευασματος.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time